Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

BACKGROUND: Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EBioMedicine
Päätekijät: Hickson, LaTonya J., Langhi Prata, Larissa G.P., Bobart, Shane A., Evans, Tamara K., Giorgadze, Nino, Hashmi, Shahrukh K., Herrmann, Sandra M., Jensen, Michael D., Jia, Qingyi, Jordan, Kyra L., Kellogg, Todd A., Khosla, Sundeep, Koerber, Daniel M., Lagnado, Anthony B., Lawson, Donna K., LeBrasseur, Nathan K., Lerman, Lilach O., McDonald, Kathleen M., McKenzie, Travis J., Passos, João F., Pignolo, Robert J., Pirtskhalava, Tamar, Saadiq, Ishran M., Schaefer, Kalli K., Textor, Stephen C., Victorelli, Stella G., Volkman, Tammie L., Xue, Ailing, Wentworth, Mark A., Wissler Gerdes, Erin O., Zhu, Yi, Tchkonia, Tamara, Kirkland, James L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
Research paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796530/
https://ncbi.nlm.nih.gov/pubmed/31542391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.08.069
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia